NICE recommends Pfizer Mylotarg in combination with chemotherapy to treat acute myeloid leukemia

recently, the NationalHealth(nice) in the UK has decided to recommend Pfizer Mylotarg in combination with chemotherapy to treat previously untreated, cd33-positive acute myeloid leukemiaabout Mylotarg
Mylotarg is an antibody-
drug(ADC) that contains monoclonal antibodies that can target CD33 and the connected cytotoxin carchamycin (calicheamicin)CD33 is an antigen expressed on the surface of myelin cells and is present in up to 90% of AML patientsWhen Mylotarg binds to the CD33 antigen, it can be absorbed into cells and then killed by releasing carkicin in cancer cellsprevious draft guidelines issued by NICE only recommend edgylotarg (gemtuzumab ozogamicin) for patients with beneficial or unknown cytogenetics, but not for patients with intermediate cytogenetics, which accounts for 65 per cent of patients with this type of disease, meaning that most patients do not have access to the drugThe drug's clinicaltrial(results show that 81% of patients taking the drug reached remissionMylotarg Treatment was approved in 2017 by the U.SFDAfor the treatment of newly diagnosed adult patients with acute myeloid leukemia (AML) that express cd33 antigensThe FDA also approved the drug for the treatment of CD33-positive AML patients 2 years of age and older who experience relapse or do not respond to initial treatmentit's worth noting that Mylotarg is the first drug to include a child's AML indications and the only AML treatment that targets CD33It was approved by Europe in May this year